L&C Bio

L&C Bio

L&C Bio was established in 2011 by Lee Hwan-chul, who remains CEO and largest shareholder. The firm operates from its headquarters in Seongnam, Gyeonggi Province, with a commercial and R&D footprint that includes offices in Seoul and Busan, a manufacturing facility in Kunshan, China, and a pharmaceutical plant in Anseong. The underlying wealth originates from the company’s core business: developing and commercializing regenerative-medicine products, human-tissue repair technologies, over-the-counter drugs, and cosmetic solutions. The investment arm deploys capital across the full corporate lifecycle — seed, start-up, early-stage, growth, expansion, late-stage, and buyout transactions — effectively functioning as the strategic venture and private-equity vehicle for the parent operating company. L&C Bio’s geographic deployment concentrates on South Korea and China, where it has a strategic partnership with Shanghai JR Life to market and distribute its flagship dermatological product, MegaDerm Plus. The firm also holds an institutional accreditation from the Association for Advancing Tissue and Biologics (AATB) for tissue processing and storage, underpinning its regulated manufacturing advantage. L&C Bio’s corporate structure includes a dedicated Internal Corporate Labor Welfare Fund alongside real-asset holdings spanning industrial headquarters, R&D centers, and a manufacturing base in Jiangsu Province. In early 2025, Lee joined the South Korean president’s economic delegation to China, signaling a deliberate push to deepen the firm’s core-strategy market presence; the firm’s China subsidiary, L&C China, was subsequently featured by the Kunshan municipal government. First-quarter 2025 operating-company revenue reached 30.3 billion won, a 70.6 percent year-over-year increase, reinforcing the cash-generation engine that funds investment activity. L&C Bio’s structural distinction lies in its dual identity as a regulated tissue-bank operator and an early-to-buyout stage investor — a posture that allows it to anchor portfolio company diligence in its own manufacturing and regulatory expertise rather than relying on external scientific advisory boards. The succession architecture remains concentrated in the founder, with no publicly disclosed separation between operating-company governance and investment-committee authority.